Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Takeda
ClinicalTrials.gov Identifier:
NCT01664624
First received: August 10, 2012
Last updated: January 22, 2014
Last verified: January 2014

August 10, 2012
January 22, 2014
July 2012
November 2012   (final data collection date for primary outcome measure)
Change From Baseline in Postprandial Area Under the Curve From Time 0 to 8 Hours (AUC[0-8]) for Active Glucagon-like Peptide-1 [ Time Frame: Baseline and Day 11; samples were taken at -15 min and -5 min (pre-meal), and 15 min, 30 min, and 1, 2, 3, 4, 6, and 8 hours (post-meal). ] [ Designated as safety issue: No ]
The concentration of glucagon-like peptide-1 (GLP-1) in blood before and up to 8 hours after eating (postprandial) was plotted and the area under the curve calculated using the linear trapezoidal rule at Baseline and on Day 11. Least squares means of the change from Baseline to Day 11 were obtained using an analysis of covariance (ANCOVA) model with treatment as fixed effect, and Baseline postprandial AUC (0-8) of active GLP-1 as a continuous covariate.
Change from Baseline in Postprandial Area Under the Curve from Time 0 to 8 Hours (AUC[0-8]) for Active Glucagon-like peptide-1 at Day 11 [ Time Frame: At Baseline and Day 11 blood samples will be collected prior to and up to 8 hours after eating ] [ Designated as safety issue: No ]
The concentration of glucagon-like peptide-1 (GLP-1) in blood before and Postprandial (after a meal) up to 8 hours after eating will be plotted and the area under the curve calculated.
Complete list of historical versions of study NCT01664624 on ClinicalTrials.gov Archive Site
  • Change From Baseline in AUC(0-8) of Postprandial Plasma Glucose [ Time Frame: Baseline and Day 11 at -15 min and -5 min (pre-meal), and 15 min, 30 min, and 1, 2, 3, 4, 6, and 8 hours (post-meal). ] [ Designated as safety issue: No ]
    The concentration of glucose in blood before and up to 8 hours after eating (postprandial) was plotted and the area under the curve calculated using the linear trapezoidal rule at Baseline and on Day 11. Least squares means of the change from Baseline to Day 11 were obtained using an ANCOVA model with treatment as fixed effect, and baseline postprandial AUC (0-8) of plasma glucose as a continuous covariate.
  • Change From Baseline in Postprandial AUC(0-8) of C-peptide [ Time Frame: Baseline and Day 11; samples were taken at -15 min and -5 min (pre-meal), and 15 min, 30 min, and 1, 2, 3, 4, 6, and 8 hours (post-meal). ] [ Designated as safety issue: No ]
    The concentration of C-peptide in blood before and up to 8 hours after eating (postprandial) was plotted and the area under the curve calculated using the linear trapezoidal rule at Baseline and on Day 11. Least squares means of the change from Baseline to Day 11 were obtained using an ANCOVA model with treatment as fixed effect, and Baseline postprandial AUC (0-8) of C-peptide as a continuous covariate.
  • Change From Baseline in Postprandial AUC(0-8) of Insulin [ Time Frame: Baseline and Day 11; samples were taken at -15 min and -5 min (pre-meal), and 15 min, 30 min, and 1, 2, 3, 4, 6, and 8 hours (post-meal). ] [ Designated as safety issue: No ]
    The concentration of insulin in blood before and up to 8 hours after eating was plotted and the area under the curve calculated using the linear trapezoidal rule at Baseline and on Day 11. Least squares means of the change from Baseline to Day 11 were obtained using an ANCOVA model with treatment as fixed effect, and Baseline postprandial AUC (0-8) of insulin as a continuous covariate.
  • Change From Baseline to Day 11 in AUC(0-8) of Appetite Sensation [ Time Frame: At Baseline and Day 11, every 30 minutes, starting 1 hour before eating until 8 hour after the meal. ] [ Designated as safety issue: No ]
    Appetite sensations were measured using a visual analog scale (VAS) questionnaire. Participants were asked to indicate their level of fullness, hunger, satiety, and prospective consumption (how much do you think you can eat?) on a 100 mm line ranging from "Not at all" (0 mm) to "extremely" (100 mm). Appetite sensation scores before and up to 8 hours after eating were plotted and the area under the curve calculated using the linear trapezoidal rule at Baseline and on Day 11. Least squares means of the change from Baseline to Day 11 were obtained using an ANCOVA model with treatment as fixed effect, and Baseline postprandial AUC (0-8) of appetite sensation VAS score as a continuous covariate.
  • Change From Baseline to Day 11 in 24-hour Average Plasma Glucose [ Time Frame: Baseline (Day -1) and Day 11, from 12 AM through 24 hours. ] [ Designated as safety issue: No ]
    Plasma glucose was measured by Continuous Glucose Monitoring System (CGMS). CGMS measures glucose every 5 minutes, starting in the fasting state 8 hour prior to the standardized breakfast (12 AM) until 16 hours after the breakfast. The average 24-hour plasma glucose concentration was calculated. Least squares means were obtained using an ANCOVA model with treatment as fixed effect, and Baseline 24-hour Glucose Measured by CGMS as a continuous covariate.
  • Changes from baseline in AUC(0-8) of postprandial glucose at Day 11 [ Time Frame: At Baseline and Day 11 blood samples will be collected prior to and up to 8 hours after eating ] [ Designated as safety issue: No ]
    The concentration of glucose in blood before and up to 8 hours after eating will be plotted and the area under the curve calculated.
  • Change from baseline in AUC(0-8) of C-peptide at Day 11 [ Time Frame: At Baseline and Day 11 blood samples will be collected prior to and up to 8 hours after eating. ] [ Designated as safety issue: No ]
    The concentration of C-peptide in blood before and up to 8 hours after eating will be plotted and the area under the curve calculated.
  • Change from baseline in AUC(0-8) of insulin at Day 11 [ Time Frame: At Baseline and Day 11 blood samples will be collected prior to and up to 8 hours after eating. ] [ Designated as safety issue: No ]
    The concentration of insulin in blood before and up to 8 hours after eating will be plotted and the area under the curve calculated.
  • Change from baseline in AUC(0-8) of appetite sensation as measured by visual analog scale (VAS) at Day 11 [ Time Frame: At Baseline and Day 11, every 30 minutes, starting 1 hour before eating until 8 hour after the meal. ] [ Designated as safety issue: No ]
    Appetite sensations will be measured using a visual analog scale questionnaire. Participants will be asked to make a point corresponding to their hunger sensation on a 100 mm line with words anchored at each end expressing the most positive or negative sensation.
  • Change from Baseline in 24-hour plasma glucose assessed by Continuous Glucose Monitoring System (CGMS) at Day 11 [ Time Frame: Baseline and Day 11 ] [ Designated as safety issue: No ]
    Patients will undergo 24-hour continuous glucose monitoring starting in the fasting state in 8 hour prior to the standardized breakfast until16 hours after the breakfast.
Not Provided
Not Provided
 
Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes
A Phase 1b, Randomized, Double-Blind, Active Comparator (Open-Label Exenatide) Controlled Study to Evaluate the Effect of Roflumilast Plus Alogliptin on Postprandial Active GLP-1 Level and 24-hour Glucose Level in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on a Stable Dose of Metformin

The purpose of this study is to assess the effect of roflumilast plus alogliptin on glucagon-like peptide-1 (GLP-1) and glucose levels in patients with type 2 diabetes.

This is a study to evaluate the antiglycemic efficacy and safety of roflumilast + alogliptin compared to alogliptin alone and roflumilast alone; it will also include an open-label exenatide treatment arm as a control. The antiglycemic efficacy of the combination will be evaluated through the measurement of postprandial active GLP-1 level, ß cell secretion activity (via the measurement of C-peptide and insulin levels), appetite sensations (as assessed by VAS) and glycemic control as assessed by a continuous glucose monitoring system (CGMS).

Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Type 2 Diabetes
  • Drug: Roflumilast
    Roflumilast tablets
    Other Name: Daxas, Daliresp
  • Drug: Alogliptin
    Alogliptin tablets
    Other Name: Nesina
  • Drug: Exenatide
    Exenatide solution
    Other Names:
    • Byetta
    • Bydureon
  • Drug: Placebo to roflumilast
    Placebo-matching roflumilast tablets
  • Drug: Placebo to alogliptin
    Placebo-matching alogliptin tablets
  • Experimental: Roflumilast + alogliptin
    Roflumilast 500 μg, tablets, orally and alogliptin 25 mg, tablets, orally, once a day for 11 days.
    Interventions:
    • Drug: Roflumilast
    • Drug: Alogliptin
  • Experimental: Alogliptin alone
    Placebo to roflumilast, tablets, orally and alogliptin, 25 mg, tablets, orally, once a day for 11 days.
    Interventions:
    • Drug: Alogliptin
    • Drug: Placebo to roflumilast
  • Experimental: Roflumilast alone
    Roflumilast 500 μg, tablets, orally and placebo to alogliptin, tablets, orally, once a day, for 11 days.
    Interventions:
    • Drug: Roflumilast
    • Drug: Placebo to alogliptin
  • Active Comparator: Exenatide
    Exenatide 5 μg subcutaneous injection twice a day for 11 days.
    Intervention: Drug: Exenatide
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
40
November 2012
November 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Male or female, aged 18 to 80 years, inclusive, at the time of dosing on Day 1.
  2. Has an historical diagnosis of type 2 diabetes mellitus (T2DM) disease.
  3. Has a documented history of a diet and exercise plan and is receiving metformin as monotherapy at a stable dose for at least 8 weeks prior to Screening; has no chronic use (>7 days) of any other antidiabetic therapy within the 8 weeks prior to Screening.
  4. Has inadequate glycemic control at Screening, as evidenced by HbA1c (glycosylated hemoglobin) level between 7.0% and 10.0%, inclusive.
  5. Has a body mass index (BMI) of ≥23.0 kg/m^2 and ≤45.0 kg/m^2, at Screening.
  6. A female of childbearing potential who is sexually active with a nonsterilized male partner agrees to use routinely adequate contraception from signing of informed consent throughout the duration of the study and for 30 days after the last dose of study drug.
  7. A male who is nonsterilized and sexually active with a female partner of childbearing potential agrees to use adequate contraception from signing of informed consent throughout the duration of the study and for 30 days after last dose of study drug
  8. In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.
  9. The participant or, when applicable, the participant's legally acceptable representative signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.

Exclusion Criteria:

  1. Has a history of type 1 diabetes.
  2. Has a history of acute metabolic diabetic complications.
  3. Has has abnormal Screening or Check-in (Day -2) laboratory values that suggest a clinically significant underlying disease (eg, active liver disease or jaundice) or participant with the following laboratory abnormalities: alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) >3 × upper limit of normal (ULN).
  4. Has a history of diabetic gastroparesis or history of gastric bypass surgery.
  5. Has a history of coronary angioplasty, coronary stent placement, coronary bypass surgery, or myocardial infarction within 6 months prior to Screening.
  6. Has New York Heart Association heart failure of Class (III-IV) regardless of therapy.
  7. Has a supine blood pressure >150 mm Hg for systolic or >90 mm Hg for diastolic, confirmed on repeat testing within a maximum of 5 minutes, at Screening and Check-in (Day -2).
  8. Has presence or history of neuropsychiatric disorder (eg, psychosis, psychotic disorders, depression associated with suicidal thinking, suicidal ideation or behavior).
  9. Has a history of drug abuse (defined as illicit drug use) or a history of alcohol abuse (defined as regular or daily consumption of more than 4 alcoholic drinks per day) within the past 2 years or is unwilling to agree to abstain from alcohol and drugs throughout the study.
  10. Has a hemoglobin ≤120 g/L for men and ≤100 g/L for women.
  11. Has a history of clinically significant allergies or idiosyncrasies to roflumilast, alogliptin and exenatide or any inactive ingredient(s) of these products, eg, rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, glucose-galactose malabsorption or phenylketonuria.
  12. Has received alogliptin or roflumilast in a previous clinical study or as a therapeutic agent within 2 months prior to Screening, or is taking prescription roflumilast for chronic obstructive pulmonary disease (COPD), or has received any other investigational compound within 30 days prior to the first dose of study medication, or is participating or plans to participate in any other clinical trial during this study.
  13. If female, is pregnant or lactating or intending to become pregnant before, during, or within 30 days after last dose; or intending to donate ova during such time period.
  14. If male, intends to donate sperm during the course of the study or for 30 days after last dose of study medication.
  15. Is an immediate family member, study site employee, or in a dependent relationship with a study site employee who is involved in the conduct of this study (eg, spouse, parent, child, sibling) or may consent under duress.
  16. Has a history of cancer, except basal cell or squamous cell carcinoma which has been in remission for at least 5 years prior to Day 1.
  17. Serum creatinine ≥1.5 mg/dL for males and ≥1.4 mg/dL for females or creatinine clearance <60 mL/minutes, based on calculation by central lab using the Cockcroft-Gault approximation at Screening Visit.
  18. Has a history of any hemoglobinopathy that may affect determination of HbA1c.
  19. Has positive test result for Hepatitis B surface antigen (HBsAg), Hepatitis C antibody (HCV), any known history of infection with human immunodeficiency virus (HIV), any acute infection, or severe immunological diseases (eg, multiple sclerosis, systemic lupus erythematosus, and progressive multifocal leukoencephalopathy).
  20. Has a risk of suicide according to the Investigator's clinical judgment per Columbia-Suicide Severity Rating Scale (C-SSRS) at Screening or has made a suicide attempt in the past 6 months.
  21. Has any clinically relevant abnormal laboratory values suggesting an unknown disease and requiring further clinical evaluation (as assessed by the investigator).
  22. Does not have an adequate standard of literacy to allow him or her to complete the study diary during non-clinic days.
  23. Has poor peripheral venous access.
  24. Has Screening or Check-in (Day -2) abnormal clinically significant electrocardiogram (ECG). Entry of any participant with abnormal not clinically significant ECG must be approved and documented by signature of Principal Investigator and Medical Monitor.
Both
18 Years to 80 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01664624
ROF-T2D_107, U1111-1128-6945
No
Takeda
Takeda
Not Provided
Study Director: Medical Director, Clinical Science Takeda
Takeda
January 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP